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Abstract: Although the branched capsular polysaccharides of Streptococcus agalactiae serotype III
(GBSIII PS) and Streptococcus pneumoniae serotype 14 (Pn14 PS) differ only in the addition of a terminal
sialic acid on the GBSIII PS side chains, these very similar polysaccharides are immunogenically
distinct. Our simulations of GBSIII PS, Pn14 PS and the unbranched backbone polysaccharide provide
a conformational rationale for the different antigenic epitopes identified for these PS. We find that
side chains stabilize the proximal βDGlc(1→6)βDGlcNAc backbone linkage, restricting rotation and
creating a well-defined conformational epitope at the branch point. This agrees with the glycotope
structure recognized by an anti-GBSIII PS functional monoclonal antibody. We find the same dominant
solution conformation for GBSIII and Pn14 PS: aside from the branch point, the backbone is very
flexible with a “zig-zag” conformational habit, rather than the helix previously proposed for GBSIII
PS. This suggests a common strategy for bacterial evasion of the host immune system: a flexible
backbone that is less perceptible to the immune system, combined with conformationally-defined
branch points presenting human-mimic epitopes. This work demonstrates how small structural
features such as side chains can alter the conformation of a polysaccharide by restricting rotation
around backbone linkages.
Keywords: capsular polysaccharide; carbohydrate antigen; molecular modeling; Group B Streptococcus;
Streptococcus pneumoniae; conjugate vaccines
1. Introduction
The bacterium Streptococcus agalactiae, usually termed Group B Streptococcus, is a primary cause of
neonatal sepsis and meningitis, particularly in infants born to carriers of the pathogen. The Streptococcus
pneumoniae bacterium is another common cause of serious infections in young infants, including
meningitis and pneumonia. Ten serotypes of Group B Streptococcus have been characterized, of which
serotype III (GBSIII) is currently the most prevalent [1]. Over 90 serotypes of Streptococcus pneumoniae
have been identified, with serotype 14 (Pn14) being the most common cause of invasive pneumococcal
disease in children prior to the introduction of conjugate vaccines [2].
Both of these gram-positive bacteria are encapsulated by polysaccharides that vary in
structure according to bacterial serotype and are essential for bacterial virulence: vaccination with
carbohydrate-protein conjugates can provide effective serotype-specific protection. The Pn14 capsular
polysaccharide (PS) is a component of all licensed conjugate vaccines since the introduction of the
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7-valent Prevenar vaccine. GBSIII PS is present in a trivalent conjugate vaccine targeting serotypes Ia,
Ib, and III that has completed phase-2 trials [3,4] and a hexavalent vaccine currently in clinical trials.
The similarity of the branched GBSIII PS and Pn14 PS has long been of interest [5]: they are
identical except that the GBSIII PS carries a terminal α(2→3)-linked sialic acid (αDNeu5Ac) on the
galactose side chain. The Pn14 PS thus has a four-residue repeat unit (RU) and the GBSIII PS a
five-residue RU, as follows.
Pn14 PS : →6)[βDGalp(1→4)]βDGlcpNAc(1→3)βDGalp(1→4)βDGlcp(1→
GBSIII PS: →6) [αDNeu5Ac(2→3)βDGalp(1→4)]βDGlcpNAc(1→3)βDGalp(1→4)βDGlcp(1→
This structural similarity of the GBSIII PS and Pn14 PS raises the possibility that type-specific
antibodies induced by one of these organisms might protect against disease caused by the other,
a phenomenon referred to as cross-protection. Indeed, vaccination with GBSIII PS has been shown
to raise two types of anti-carbohydrate antibody: a major population recognising the native PS but
not the desialylated PS (equivalent to Pn14 PS) and a minor population that cross-reacts with Pn14
PS. However, the converse has not been found to be true: antibodies elicited by Pn14 PS are not
protective against GBSIII bacteria, although desialylation of the GBSIII PS significantly increases
the cross-reactivity with Pn14 antibodies [6,7]. Evidence for serotype cross-protection is necessarily
indirect and complicated by the fact that cross-reaction of a PS with antibody raised by a different PS
does not reliably predict cross-protection: vaccination raises families of antibodies against various PS
epitopes, not all of which are of high avidity and thus effective opsonophagocytic (killing) antibodies.
Indeed, effective cross-protection between GBSIII and Pn14 has not been demonstrated: antibodies
elicited by Pn14 PS (desialylated GBSIII PS) are not protective against GBSIII bacteria and there is
considerable evidence that the presence of the terminal sialic acid residue is essential for the elicitation
of protective antibodies against GBSIII PS [6–9].
The native PS produced by GBSIII and Pn14 contains between 50 and 300 RU, which is far longer
that the epitope bound by an antibody. There has been some effort expended into identification of the
minimal epitope for both GBSIII PS and Pn14 PS, with some conflicting results (Figure 1). Originally,
on the basis of NMR measurements and molecular modeling, a long 3–4 RU helical conformational
epitope for GBSIII PS was proposed (Figure 1a), with the Pn14 PS being comparatively flexible
and disordered. The antigenic differences between GBSIII and Pn14 were thus originally attributed
to significantly different PS conformations (and hence conformational epitopes), rather than direct
interaction of the antibody with the sialic acid side chain in GBSIII PS [9–12]. The hypothesis was that
anti-GBSIII antibodies bind the helical GBSIII PS backbone (stabilized by the sialic acid residues on the
exterior surface of the helix) and not the sialylated side chain, with a 3 to 4 RU epitope necessary for
raising protective antibodies.
However, this hypothesis is challenged by later work that provides evidence that a helical
conformational epitope of GBSIII PS is not required for antigen recognition and that the sialic acid
participates directly in antibody recognition of GBSIII. Safari et al. investigated the epitope specificity
of GBSIII and showed that human anti-GBSIII PS antibodies recognized the linear backbone epitope
common to Pn14 PS and GBSIII PS: -Glc-GlcNAc-Gal- (Figure 1b) [7]. However, although conjugates of
linear oligosaccharides of GBSIII PS (such as Gal-Glc-GlcNAc, Glc-GlcNAc-Gal, and GlcNAc-Gal-Glc)
did evoke specific oligosaccharide antibodies in mice, these antibodies bound neither native nor
desialylated GBSIII PS. Therefore, it was assumed that they are too small or flexible to raise antibody
and longer chain lengths exhibiting this epitope are required. Furthermore, the recent elucidation
of the crystal structure of a short six-sugar GBSIII epitope in complex with a functional antibody
showed a branched hexasaccharide functional epitope with sialic acid participating directly in antigen
binding [13]. Identification of a short epitope for GBSIII is valuable information for the development of
synthetic vaccines, due to the difficulty and cost associated with synthesis of longer oligosaccharides.
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Figure 1. Schematic representation of the protective epitopes previously identified for GBS PS (left
column) and Pn14 PS (right column). GBSIII: (a) 3–4 RU helical conformational epitope postulated
for GBSIII PS [10,11]; (b) the linear backbone epitope identified from fragment binding to GBSIII
antibodies [14] and (c) a 6-residue epitope identified from a DP2-Fab crystal structure [13]. Pn14: (d) the
tetrasaccharide epitope first identifed by Safari et al. [7,14] and then by Kurbatova et al. [15] from
antibody studies. Structures are depicted using the ESN symbol set [16] with yellow circle: Gal, blue
circle: Glc, blue square: GlcNAc, purple diamond: Neu5Ac.
Effective short, branched epitopes have also been identified for the Pn14 PS: Safari et al.
demonstrated that one RU of the Pn14 PS (Figure 1c) is essential and sufficient for inducing protective
Pn14-specific antibodies: the presence of the trisaccharide branch point in an epitope is crucial for
anti-Pn14 antibody recognition and the extra galactose contributes to the immunogenicity of the
epitope [14]. Kurbatova et al. recently identified a similar branched tetrasaccharide as the most
effective epitope for Pn14 PS [15]. In contrast, linear Pn14 PS fragments were found to be completely
ineffective: none of a range of short linear epitopes of the PS backbone were recognized by Pn14
antibodies [7]. Only branched fragments containing the Gal-Glc-(Gal-)GlcNAc moiety were found to
provide significant protection.
Identification of the capsular polysaccharide epitopes recognized by protective antibodies
(or glycotopes) and their conformation is crucial for understanding the affinity and specificity of
carbohydrate-antibody interactions and, ultimately the cross-protection mechanisms. Furthermore,
identification of the conformational effect of side chains on PS conformation may usefully inform
optimal antigen design and the development of effective conjugate vaccines. However, as direct
experimental evidence of the key PS epitopes is difficult to obtain, systematic molecular modeling
protocols have been developed to provide a theoretical estimate of carbohydrate conformation
and dynamics [17]. In the last decade, a considerable improvement in both carbohydrate force
fields [18–21] and computer hardware has facilitated far larger, longer and more accurate computer
simulations of polysaccharides than was possible when the previous simulations of GBSIII/Pn14 PS
were performed. Therefore, we considered it timely to embark on more extensive modeling of these
capsular polysaccharides. Our aim is to shed light on the remaining unanswered questions on the
conformations of the GBSIII and Pn14 PS, including the following. Does the GBSIII PS have a helical
conformation? Are the conformation and dynamics of the GBSIII PS significantly different to Pn14
PS? What are the likely minimal epitopes for these two PS? Why are some fragments more effective
antigens than others?
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To answer these questions, we compare the solution conformation and dynamics of the GBSIII
and Pn14 PS, as well as the corresponding unbranched saccharide, to determine the effects of the side
chains on the polysaccharide backbone conformation. We ran long simulations of 1 µs, an order of
magnitude more than the previous simulations of 50 ns.
We do not consider O-acetylation of the terminal αDNeu5Ac sialic acid residues [22], as O-acetylation
was not found to be necessary for elicitation of functional antibodies against GBSIII [23]. We find that
contrary to previous simulations, the polysaccharide backbone dynamics is almost identical in the GBSIII
and Pn14 polysaccharides. The backbone is not helical, but rather has a highly flexible zig-zag conformation,
whereas the branch points are relatively inflexible with well-defined conformational epitopes. In contrast,
the unbranched PS is highly flexible and conformationally varied. Our results are supported by NMR
NOESY experiments performed on the GBSIII polysaccharide.
2. Materials and Methods
Our established systematic approach to modeling of polysaccharide antigens involves first
determining the preferred conformations of each of the glycosidic linkages in the polysaccharide
by calculation of the φ, ψ potential of mean force (PMF) for the corresponding disaccharides and
then progresses to molecular dynamics simulations of three- and six-RU oligosaccharides in aqueous
solution to establish the preferred conformations and dynamics of the carbohydrate chains [24–26].
2.1. Disaccharide PMF Calculations
We identified the preferred conformations of the each of the glycosidic linkages in isolation
by calculation of the potential of mean force (PMF) for rotation about the φ and ψ dihedral
angles. PMFs were calculated using the metadynamics [27] routine incorporated into NAMD [28]
with the glycosidic linkage torsion angles used as collective variables. For the three-bond (1→6)
linkages, we calculated a two-dimensional PMF as a function of φ and ψ only, allowing the ω
dihedral to rotate freely. All PMF surfaces were calculated in gas-phase, except for the charged
αDNeu5NAc(2→3)βDGalp disaccharide, which required simulation in explicit aqueous solution with a
neutralizing counter-ion. Gas phase PMFs for uncharged disaccharides have been demonstrated to be
a reasonable approximation to solution PMF in a polysaccharide [25,29,30].
2.2. Molecular Dynamics Simulations
All simulations were performed with the NAMD molecular dynamics program [28] version 2.12
(employing NAMD CUDA extensions for calculation of long-range electrostatics and nonbonded
forces on graphics processing units [31]). Carbohydrates were modeled with the CHARMM36 additive
force field for carbohydrates [19,32] and water was simulated with the TIP3P model [33].
Initial configurations of three-repeat (3 RU) and six-repeat unit (6 RU) oligosaccharides for GBSIII
and Pn14 PS were built using our in-house CarbBuilder software [34,35] which employs the psfgen
tool to create “protein structure” (psf) files for modeling with the CHARMM force field and the NAMD
molecular dynamics program. These initial oligosaccharide structures were optimized through 20,000
steps of standard NAMD minimization in vacuum and then solvated (using the solvate plugin to the
Visual Molecular Dynamics (VMD) [36] analysis package) in a periodic cubic unit cell with randomly
distributed sodium ions to electrostatically neutralize the system.
All MD simulations were preceded by a 30,000 step minimization phase, with a temperature
control and equilibration regime involving 10 K temperature reassignments from 10 K culminating
in a maximum temperature of 300 K. Equations of motion were integrated using a Leap-Frog Verlet
integrator with a step size of 1 fs and periodic boundary conditions. Simulations were performed
under isothermal-isobaric (nPT) conditions at 300 K maintained using a Langevin piston barostat [37]
and a Nose-Hoover [38,39] thermostat.
Long-range electrostatic interactions were treated using particle mesh Ewald (PME) summation,
with κ = 0.20 Å−1 and 1 Å PME grid spacing. Non-bonded interactions were truncated with a
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switching function applied between 12.0 and 15.0 Å to groups with integer charge. The 1–4 interactions
were not scaled, in accordance with the CHARMM force field recommendations.
Each metadynamics simulation comprised a 1500 ns MD simulation, with a Gaussian hill height
of 0.5 and width of 2.5 degrees. Structures were collected at intervals of 250 ps for analysis. For the
solution simulation, the αDNeu5NAc(2→3)βDGalp disaccharide was placed in the center of a cubic
box with sides of 30 Å. The box was filled with approximately 2500 water molecules and a single Na+
counter ion.
The 3RU strands were placed in the center of a cubic water box with sides of 60 Å, while the 6RU
strands employed a box of length 80 Å. The Pn14 strands were solvated with 6810 (3RU) and 16,313
(6 RU) water molecules, while the GBSIII strands used 6790 (3 RU) and 16,279 (6 RU) water molecules.
The GBSIII systems were neutralized with 3 (3 RU) and 6 (6 RU) Na+ ions. In each case, the system was
equilibrated 0.03 ns with a cycled temperature increase from 0 K to 300 K in 10 K increments with each
cycle commencing with a 10,000 step energy minimization followed by a 0.001 ns MD simulation at the
specified temperature until 300 K. The 3 RU MD simulations ran for 250 ns and the 6 RU simulations
ran for 1 µs.
2.3. Data Analysis
In this work, two-bond (1→X) glycosidic linkages are defined by the torsion angles φ =
H1′–C1′–OX–CX and ψ = C1′–OX–CX–HX. The (2→3) glycosidic linkages use φ = C1′–C2′–O3–C3
and ψ = C2′–O3–C3–H3. These definitions for φ and ψ are analogous to φH and ψH in IUPAC
convention. For the (1→6) glycosidic linkage, the three dihedral angles are defined as φ =
H1′–C1′–O6–C6, ψ = C1′–O6–C6–C5 and ω = O6–C6–C5–O5.
Analysis of the simulations used time series frames 25 ps apart, discarding the first 100 ns as
equilibration. Molecular conformations extracted from the MD simulations were depicted with VMD,
where necessary using the PaperChain visualization algorithm for carbohydrates [40] to highlight the
hexose rings. Dihedral angles from the simulations and the DP2-Fab complex crystal structure (PDB
ID code 5M63) were extracted using VMD’s Tcl scripting interface and statistical values calculated
with in-house Python scripts. The DP2 fragment comprises RU2 with a terminal 2,5-anhydro-D-Man.
The GBSIII 6RU simulation conformations and the DP2-Fab complex crystal structure were aligned for
comparison on the ring atoms of the αDNeu5NAc(2→3)βDGalp(1→4)βDGlcpNAc branch point.
Conformations from both 3RU trajectories were clustered using VMD’s internal measure cluster
command to calculate clusters according to the quality threshold algorithm [41]. Frames were aligned
on the GlcNAc residues in RU1 to RU5 of the 6RU chains. Clustering was then performed with a
cut-off of 7 Å on an RMSD fit to the atoms in the backbone residues of RU1 to RU5.
2.4. NMR Analysis
The GBSIII polysaccharide sample (10 mg) was lyophilized and exchanged twice with 99.9%
D2O (Sigma Aldrich, Pty. Ltd., Johannesburg, South Africa), then dissolved in 600 µL of D2O and
introduced into a 5 mm NMR tube for data acquisition. 1D 1H and 13C and 2D, COSY, TOCSY, NOESY,
HSQC, HMBC and hybrid HSQC-TOCSY and HSQC-NOESY spectra were obtained using a Bruker
Avance III 600 MHz NMR spectrometer (Bruker BioSpin AG, Fällanden, Switzerland) equipped with
a BBO Prodigy cryoprobe and processed using standard Bruker software (Topspin 3.2). The probe
temperature was set at 343 K. The 2D TOCSY experiment was performed using a mixing time of
180 ms and the 1D variants using a mixing time of 200 ms. The 2D NOESY experiment was performed
using a mixing times of 300 and 500 ms and the 1D variants using mixing times of 300, 400 and
500 ms. The 1H-13C HSQC and HMBC experiments were optimized for J = 145 Hz and 8 Hz, and the
HSQC-TOCSY and HSQC-NOESY experiments were recorded using mixing times of 120 and 250 ms,
respectively. 2D experiments were recorded using non-uniform sampling: 50% for homonuclear and
25% for heteronuclear experiments. Spectra were referenced relative to the H3ax/C3 signal of terminal
sialic acid: 1H at 1.79 ppm and 13C at 40.68 ppm [42].
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3. Results
Our 1 µs simulations of 6 RU show that polysaccharides with the →6)βDGlcpNAc(1→3)βD
Galp(1→4)βDGlcp(1→ backbone are all extremely flexible, with none of the well-defined conformations
we have found in other, linear bacterial polysaccharides [24,25]. However, a closer inspection of the
range of motion for GBSIII PS, Pn14 PS and the unbranched backbone PS reveal a common dominant
conformational habit, as well as significant differences in flexibility.
3.1. PS Chain Conformations
In Figure 2, we quantify range of motion for these very flexible polysaccharides with the simple
end-to-end distance, r, measured between the GlcNAc O5 atoms in repeat units RU1 and RU6
(illustrated on a sample conformation in Figure 2a). Comparison of the time series (Figure 2, center
column) and distribution (right column) of r shows that GBSIII PS is the most conformationally defined,
and the unbranched polysaccharide backbone the most flexible, of the three molecules. Only 12% of
the GBSIII PS conformations have r < 40 Å, as compared to 25% for Pn14 and 33% for the unbranched
backbone. Overall, the unbranched backbone is less extended (more globular) than the branched
polysaccharides and shows more rapid conformational transitions (compare time series plots in
Figure 2b–d). The corresponding mean squared end-to-end distances for the simulations reflect this
trend: 2505 Å (GBSIII), 2157 Å (Pn14) and 1993 Å (backbone).
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Figure 2. Polysaccharide end-to-end distance distributions for the 6RU PS. (a) The molecular end-to-end
distance, r, is defined as the distance between O5 atoms in GlcNAc residues in RU1 and RU6,
here shown on the GBSIII PS. The center column shows the r time series for (b) GBSIII PS, (c) Pn14
PS and (d) unbranched backbone PS. The corresponding distance distributions are in the rightmost
column for (e) GBSIII PS, (f) Pn14 PS and (g) the unbranched backbone PS.
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Although flexible, the GBSIII PS and Pn14 PS have a similar dominant overall conformation
with 48 < r < 58 Å. Here the PS backbone has an overall “zig-zag” arrangement, bending at the
1→6 linkage, with the side chains exposed at the branch points, as shown in the GBSIII schematic in
Figure 3a and the sample conformation in Figure 3b.
(a) (b)
Figure 3. The ‘zig-zag’ conformational habit of GBSIII and Pn14 PS. (a) Schematic representation with
the ESN symbol set [16] (yellow circle: Gal, blue circle: Glc, blue square: GlcNAc, purple diamond:
Neu5Ac) and (b) a representative 6RU GBSIII PS simulation snapshot. Residues are highlighted as
follows: Glc and GlcNAc: blue; Gal: yellow; sialic acid: purple.
This conformation is in very good agreement with the new antibody binding model recently
proposed for GBSIII PS (see Figure 5 in Carboni et al. [13]). Figure 4 shows the GBSIII PS conformations
from our 6RU simulation superimposed on the solved crystal structure for DP2-Fab. The zig-zag
conformation of the backbone exposes the sialic acid side chain for binding (Figure 4a) with the
flexible backbone held well away from the antibody over the course of the simulation (Figure 4b).
Conversely, we find no evidence in our simulations to support the helical model for GBSIII PS
previously proposed [10,11]. Further, in the zig-zag conformation, the polysaccharide backbone is
relatively inaccessible to antibody binding.
However, although the 6RU backbone shows the same dominant conformation for GBSIII PS,
Pn14 PS and the unbranched backbone PS, they have a significant difference in flexibility. Clustering
of the simulation conformations shows that, while GBSIII PS is in this general zig-zag conformational
family for 85% of the simulation, Pn14 PS is more flexible and is in a zig-zag for 78% of the simulations,
moving occasionally into alternative, more bent conformations (with smaller r). The unbranched
backbone polysaccharide is the most disorganised, with the zig-zag appearing for 66% of the simulation
and showing significant sub-populations of globular conformations (with r < 25 Å).
The source of the conformational differences between the polysaccharides is a conformational
constraint on the βDGlc(1→6)[βDGal(1→4)]βDGlcNAc linkage in GBSIII PS and, to a lesser extent,
in Pn14 PS. The conformation and flexibility of the other backbone linkages (βDGlcpNAc(1→3)βDGalp
and βDGalp(1→4)βDGlcp) is very similar in all three polysaccharides—see a detailed analysis in
Appendix A, particularly Figure A1. However, for the βDGlcp(1→6)βDGlcpNAc linkage, proximity of
the side chains impose a restriction on rotation, as follows.
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(a) (b)
Figure 4. GBSIII 6RU structures superimposed on the bound branch point of the DP2-FAb crystal
structure from Carboni et al. [13] (PDB ID code 5M63): (a) a single representative structure and
(b) superimposed conformational snapshots at 12.5 ns intervals (with the first 125 ns discarded
as equilibration).
3.2. Conformations of the 1→6 Linkage
Figure 5 provides a comparison of the flexibility of the three-bond glycosidic linkage in a
βDGlcp(1→6)βDGlcpNAc disaccharide and the GBSIII PS, Pn14 PS and unbranched backbone PS.
The three dihedral angles describing rotation about the three bonds in the (1→6) glycosidic linkage are
here defined as φ = H1′–C1′–O6–C6, ψ = C1′–O6–C6–C5 and ω = O6–C6–C5–O5. These dihedrals are
labeled on the GBSIII fragment in Figure 5, left. A PMF energy surface for the (1→6) glycosidic linkage
has, therefore, three dimensions. However, for ease of visualization and comprehension, we show
only 2D projections of the 3D volume: the φ, ψ PMF (Figure 5a) and the φ, ω PMF surface (Figure 5b)
for a βDGlc(1→6)βDGlcNAc disaccharide in the gas phase. These PMF surfaces illustrate the range
of motion possible for an unrestrained linkage. The φ, ψ PMF in Figure 5a reveals that the central
bond in the linkage described by the ψ dihedral is relatively flexible, with multiple minima within
the 2 kcal·mol−1 contours: a global minimum conformation at ψ = 71◦, a secondary anti minimum
conformation at ψ = −179◦ and a tertiary minimum in the ψ = −60 region. In contrast, rotation about
the φ dihedral is much more constrained, with a broad global minimum around 0◦ < φ < 75◦ and a
narrow secondary well at φ = 160◦. The φ, ω PMF surface in Figure 5b confirms these minima for φ and
shows the expected three minima for the ω dihedral, which are by convention termed gg (ω ≈ −60◦),
gt (ω ≈ 60◦) and tg ω ≈ 180◦). Glucopyranosides are expected to be primarily in the gg conformation,
with the gg:gt:tg population ratios approximately 6:4:0 [43].
As a comparison to the unrestrained disaccharide, the range of motion actually explored during
the simulations of the 6RU oligosaccharides is revealed by the corresponding dihedral time series
scatter plots superimposed on the disaccharide PMFs. The restriction of the βDGlc(1→6)βDGlcNAc
linkage in GBSIII is apparent in the time series scatterplots for the 6RU GBSIII oligosaccharide strand
(Figure 5, second column). These confirm a single dominant conformer for GBSIII, with average torsion
angle values φ, ψ, ω = 51◦, −175◦, −67◦ (standard deviations = 10, 11, 8 respectively). These angles are
compatible with the GBSIII DP2-Fab complex crystal structure where this linkage has φ, ψ, ω = 51◦,
140◦, −70◦ (indicated by ‘X’ on the PMF plots in Figure 5a,b). The central 1→6 linkage in GBSIII
PS is in this dominant conformation for 100% of the simulation and the ω dihedrals remain in the
low-energy gg conformation for the duration.
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Figure 5. Rotation of the three-bond βDGlc(1→6)βDGlcNAc linkages in GBSIII, Pn14 and the
unbranched backbone PS. The φ, ψ and ω angles describing the orientation of this linkage are labeled
on the GBSIII fragment shown on the left. Contoured 2D (a) φ, ψ PMF and (b) the φ, ω PMF surfaces
for a βDGlc(1→6)βDGlcNAc disaccharide in the gas phase illustrate the range of motion possible for an
unrestrained linkage. Contours are drawn at intervals of 1 kcal·mol−1 to a maximum of 12 kcal·mol−1
and ‘X’ markers indicate dihedral angle values from the six-sugar GBSIII epitope identified in the
DP2-Fab crystal structure [13]. The range of motion actually explored by the 6RU oligosaccharides
is demonstrated with time series scatter plots of the two central βDGlc(1→6)βDGlcNAc linkages in
the 6RU strands superimposed on the PMFs as follows: (c) GBSIII φ, ψ; (d) GBSIII φ, ω; (e) Pn14 φ, ψ;
(f) Pn14 φ, ω; (g) unbranched backbone φ, ψ; and (f) unbranched backbone φ, ω.
The average torsion angle values for Pn14 PS are φ, ψ, ω = 50◦, 180◦, −62◦ (standard deviations =
12, 18, 26 respectively). The central βDGlc(1→6)βDGlcNAc linkage is in the dominant conformation
(equivalent to the GBSIII PS) for 91% of the simulation. The increase in standard deviation for the φ
and ω dihedrals relative to GBSIII PS is indicative of increased flexibility and alternative conformations
of the ω dihedral, which shows a ratio of approximate 10:1 of gg to gt conformations, with no tg
conformations appearing. Therefore, the 1→6 linkage shows a slight increase in flexibility relative to
GBSIII PS, which is cumulative with increasing chain length. This reflects the increased constraint on
the backbone imposed by the terminal sialic in the GBSIII side chain.
The 1→6 linkage is markedly more flexible in the unbranched backbone saccharide and the zig-zag
conformation drops to 86% of the simulation. The average torsion angle values for the unbranched
backbone are φ, ψ, ω = 50◦, −179◦, −69◦ (standard deviations = 15, 22, 30 respectively). In particular,
the ω dihedral has an 8% population of gt conformations and a small population of tg conformations.
In addition, both the φ and ψ dihedrals show a broader range of rotation.
Interestingly, we saw no effect on conformation and dynamics of increasing chain length.
Our simulations of 3RU for GBSIII and Pn14 PS showed the same dihedral populations as the middle
linkages in the 6RU simulations (data not shown). Further, we performed a 250 ns simulation of
the effective branch epitope previously identified (Figure 1d) [14,15]. This molecule shows the same
conformation of the branch point and other dihedrals as Pn14 PS (see Appendix B, Figure A2) and is
thus a faithful representation of the branch point in the Pn14 PS.
3.3. Inter-Residue Atomic Contacts in GBSIII
In GBSIII PS, interactions between the side chain and the backbone residues stabilize the
conformation of the 1→6 linkage. We compare the simulation data with NMR NOESY experiments on
the GBSIII PS, focussing on inter-residue NOEs that are diagnostic for close proximity of the side chain
to the backbone.
In GBSIII PS, hydrogen bonding interactions between the side chain sialic acid (SA) and side
chain Gal (Gal’) and the backbone Glc and Gal stabilize the conformation of the 1→6 linkage,
as follows. Transient hydrogen bonds occur between the bound SA O9 and backbone Gal O2
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(shown in Figure 6a) as well as SA O9 – Glc O3 and SA O8 – Glc O2 hydrogen bonds (occasionally
simultaneous, as in Figure 6b). The crystal structure for the GBSIII PS fragment in DP2-Fab shows
a close hydrogen bond between SA O9 and and the Glc O6, with distance of 2.8 Å [13]. We do
not find this hydrogen bond in our simulations, although the atoms come within 4 Å of each other.
This is due to the fact that the sialic acid is in an alternative (higher energy) conformation in the
crystal structure—possibly stabilized by interactions with the antibody. The conformation of this
sialyl linkage is known to have no fixed standard conformation and to be heavily dependent on the
molecular environment [44]. See Appendix A and Figure A1e for more detailed analysis of the sialic
acid conformation. Unfortunately, considerable overlap between the signals of the NAc group of SA
and GlcNAc precluded investigation of contact between the sialic acid side chain and the backbone in
GBSIII, as previously reported [13].
Additional hydrogen bonds occur between the Gal’ O2 and backbone Glc O3 in both the GBSIII PS
and Pn14 PS simulations. In this case, NMR signals are better resolved: a series of 1D and 2D NOESY
experiments gave key H1 Glc crosspeaks to H4, H5 and both H6s of the neighboring GlcNAc (consistent
with the βDGlc(1→6)[βDGal(1→4)]βDGlcNAc linkage) as well as small additional correlations to the
main chain repeating unit (Figure 6c(iii)). In particular, peaks for H1 Glc to H1 Gal’ as well as H1 Glc
to H3 Gal’ provide evidence for close proximity of the side chain to the backbone and are consistent
with our simulations. This is corroborated by 2D NOESY cross peaks, as well as peaks from the
well-resolved H2 of Glc at 3.36 ppm to H1 and H3 of Gal’ (Figure 6c(iv)).
(c)
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Figure 6. Inter-residue contacts in GBSIII PS. (a) Example of SA O9–Gal O2 hydrogen bond between
the side chain and the backbone residues. (b) Example of simultaneous SA O9–Glc O3 and SA O8–Glc
O2 hydrogen bonds. (c) Overlay of 1D NMR experiments of GBSIII PS showing (i) 1D proton spectrum;
(ii) 1D TOCSY (200 ms) with irradiation of H2 Glc; (iii) 1D NOESY (500 ms) with irradiation of H1 Glc;
and (iv) 1D NOESY (500 ms) with irradiation of H2 Glc.
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4. Discussion
This modeling study shows that the polysaccharide backbone conformation is very similar
in the GBSIII and Pn14 polysaccharides, albeit with increased flexibility for Pn14 PS. Both GBSIII
and Pn14 PS exhibit a constrained branch epitope and a flexible zig-zag backbone. The zig-zag
conformation is in remarkable agreement with the binding model for GBSIII PS proposed by
Carboni et al. [13]. The βDGlc(1→6)[βDGal(1→4)]βDGlcNAc branch point is a relatively rigid
and exposed component of the flexible backbone, and thus a likely site for antibody binding.
This stationary branch point is in agreement with preclinical evidence that has indicated that the
Pn14 branching element βDGalp(1→4)]βDGlcpNAc is necessary and sufficient for induction of an
effective antibody response [14]. Further, the lack of accessibility of the backbone in GBSIII and
Pn14 PS to antibody binding together with increased flexibility and alternative conformations of the
unbranched backbone provides a rational for why antibodies to linear oligosaccharide fragments of
GBSIII PS (such as Gal-Glc-GlcNAc, Glc-GlcNAc-Gal, and GlcNAc-Gal-Glc) bound neither GBSIII
PS nor Pn14 PS [7]. In addition, the lack of extended conformational epitopes supports experimental
data that finds short epitopes to be effective for GBSIII and Pn14, epitopes comprising solely their
respective branch points and side chain (i.e., βDGlc(1→6)[αDNeu5Ac(2→3)βDGal(1→4)]βDGlcNAc
and βDGlc(1→6)[βDGal(1→4)]βDGlcNAc, respectively). This is consistent with the DP2-Fab crystal
structure elucidated by Carboni et al.: the binding involves the branch and does not require a
conformational epitope [13].
Kurbatova et al. identified a βDGalp(1→4)βDGlcp(1→6)[βDGalp(1→4)]βDGlcpNAc
tetrasaccharide as the most effective epitope for Pn14 PS, as compared to hexa- and octasaccharides in
a mouse model [15]. Our work provides a possible explanation for this: vaccination with this primary
epitope could raise a single class of effective antibody, as opposed to a family of antibodies raised by
the more flexible hexa- and octasaccharides, thus making this short chain more protective. In contrast,
the hexa- and octasaccharides could potentially present epitopes not present in the polysaccharide,
as seen in the unbranched backbone.
The flexible zig-zag conformation and stationary branch point were not identified for the Pn14 PS
in the earlier study. In contrast to the small 8% population of the gt conformation in Pn14 that we see
in these simulations, in the 5RU simulations with the AMBER force field by González-Outeiriño et al.
the Pn14 oligosaccharide showed a nearly 50:50 mixture of the gg to gt rotamers, whereas the GBSIII
PS remained almost constantly in the gg conformation. This discrepancy was attributed to an anomaly
arising from insufficient equilibration in the 50 ns simulations [10]. Therefore, the extreme flexibility
of Pn14 PS and disordered structure as compared to GBSIII PS suggested by this prior work could
be a consequence of the increased flexibility of this dihedral in the AMBER force field as compared
to the CHARMM force field. In the presence of competing computational models, experimental
evidence is key. The DP2-Fab crystal structure provides evidence that a short strand can effectively
bind to an antibody and that a helical conformation of the backbone is not necessary for antigen
binding. In addition, we observed inter-residue NMR NOEs for the GBSIII PS that are consistent with
our simulations.
The branches of the GBSIII and Pn14 PS both present common terminal glycan epitopes:
3-Sialyl-N-acetyllactosamine is present in human biofluids and is a common sequence terminating
N- and O-glycans on the surface of all mammalian cells, while the shorter βDGalp(1→4)]βDGlcpNAc
constitutes the ubiquitous LacNAc building block in mammalian N-linked protein glycans. In general,
mimics of mammalian cell surface residues can subvert the immune system.
This work thus suggests a strategy for bacterial evasion of the host immune system: expression of
a very flexible backbone that is shielded from the immune system by both its zig-zag conformation
and hyper-mobility, combined with exposed, inflexible branches that present human-mimic epitopes.
This strategy should be considered with other polysaccharides with similar backbones and human-like
branch epitopes, where it is likely that the branch points will be key to immunogenicity.
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In summary, this work demonstrates how small structural features such as side chains can alter the
conformation of a polysaccharide by restricting rotation around backbone linkages. It also highlights
the explanatory power of simulation for optimal antigen design and the development of effective
conjugate vaccines.
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Appendix A. Analysis of Glycosidic Linkages
The GBSIII glycosidic linkages can be conveniently classified into the three linkages which make
up the common polymer backbone and the two glycosidic linkages which comprise the side chains.
The contoured disaccharide φ, ψ PMF energy surfaces for disaccharides representing all the constituent
linkages in GBSIII (Pn14 and the backbone being subsets) are shown in the left column of Figure A1.
The three linkages which make up the common polymer backbone are shown in the top three rows
and the two glycosidic linkages which comprise the side chains in the bottom two rows.
Appendix A.1. βDGlcNAc(1→3)βDGal
The βDGlcNAc(1→3)βDGal backbone linkage is flexible: the φ, ψ PMF (Figure A1a, left) shows
a broad, shallow central well, encompassing the global energy minimum at φ, ψ = 54◦, 16◦, and a
secondary syn-syn minimum at φ, ψ = 44◦, −54◦ with ∆G = 1 kcal·mol−1. This is compatible with the
GBSIII DP2-Fab complex crystal structure [13], where this linkage has angles equivalent to φ, ψ = 35◦,
−9◦ (indicated by ‘X’ on the PMF plot). In addition, the tertiary anti-ψ minimum is also relatively low
in energy (∆G = 1.5 kcal·mol−1), albeit with a high energy barrier to rotation of >6 kcal·mol−1.
The time series scatter plots for this linkage in GBSIII, Pn14 and the unbranched backbone
show that all 6RU oligosaccharides explored the full range of linkage conformations in the central
well, with the average φ,ψ value showing a shift to favor the secondary well in solution (Table A1).
This is in agreement with the reported behaviour of this linkage in the sialyl Lewis X pentasaccharide
(sLeX-5) for a 500 ns MD simulation at 37 ◦C in explicit water [45]. However, transitions to the anti-ψ
conformation occurred rarely throughout the duration simulations. This is in contrast to sLeX-5,
where the unconstrained terminal βDGal showed a significant population of the anti-ψ conformation.
This difference is likely due to the more constrained environment in the oligosaccharides, as our
βDGlcNAc(1→3)βDGal vacuum PMF is very similar to the energy map calculated for this linkage
in sLeX-5. Indeed, the previous 5RU simulations of GBSIII and Pn14 by González-Outeiriño et al.
showed an even smaller range of motion for the βDGlcNAc(1→3)βDGal linkage, encompassing only
the vacuum global energy minimum (Table A1). This can be attributed to limited conformational
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sampling in the earlier 50 ns simulations, as transitions between the two minima in the central well
occurred on a 20- to 50 ns time scale in our oligosaccharide simulations.
Figure A1. The left column shows contoured disaccharide φ, ψ PMF surfaces
for (a) βDGlcNAc(1→3)βDGal, (b) βDGal(1→4)βDGlc, (c) βDGlc(1→6)βDGlcNAc,
(d) βDGal(1→4)βDGlcNAc and (e) αDNeu5Ac(2→3)βDGal. The PMF for the charged
αDNeu5Ac(2→3)βDGal disaccharide is in solution, all others are gas-phase. Contours are
drawn at intervals of 1 kcal·mol−1 to a maximum of 12 kcal·mol−1 and ‘X’ markers indicate dihedral
angle values from the six-sugar GBSIII epitope in complex with Fab crystal structure [13]. Scatter plots
of the corresponding two central linkages in the 6RU oligosaccharide strands for the last 900 ns of
simulation time are superimposed on the PMFs for 6RU of GBSIII (column 2, green), Pn14 (column 3,
red) and the unbranched backbone (right column, purple).
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Table A1. Average values of the glycosidic dihedrals in degrees for the two middle repeating
units of 6 RU of GBSIII and Pn14 and the unbranched backbone, including comparison with
González-Outeiriño et al. [10] (standard deviations in parenthesis). * Note that the 1→6 linkage
comprises three diehdrals.
PMF GBSIII Pn14 Backbone
φ, ψ, ω φ, ψ, ω φ, ψ, ω
βDGlcNAc(1→3)βDGal 54, 16 45 (12), −22 (25) 45 (13), −20 (27) 44 (12), −23 (26)
González-Outeiriño et al. 42 (13), 2 (18) 41 (12), 1 (19)
βDGal(1→4)βDGlc 56, −1 47 (14), −14 (40) 49 (15), −14 (37) 49 (14), −17 (46)
González-Outeiriño et al. 47 (12), 8 (12) 43 (12), −7 (16)
βDGlc(1→6)βDGlcNAc * 26, 71 51 (10), −175 (11), −67 (8) 50 (12), −180 (18), −62 (26) 50 (15), −179 (22), −69 (30)
González-Outeiriño et al. 41 (10), −159 (22), −67 (9) 40 (14), −167 (31), −65 (10)
βDGal(1→4)βDGlcNAc 49, 1 50 (10), 0 (14) 50 (11), −2 (18)
González-Outeiriño et al. 39 (10), 5 (10) 43 (11), 5 (11)
αDNeu5Ac(2→3)βDGal −66, 1 −70 (21), −8 (19) -
González-Outeiriño et al. −173 (14), −11 (11)
Appendix A.1.1. βDGal(1→4)βDGlc
The βDGal(1→4)βDGlc linkage is also flexible. The φ, ψ PMF (Figure A1b, right) has a single
central syn-syn well with the global energy minimum at φ, ψ = 56◦, −1◦ and both a narrow anti-φ
minimum (∆G = 0.5 kcal·mol−1) and an anti-ψ minimum (∆G = 3.6 kcal·mol−1). In the crystal structure
of the six-sugar GBSIII epitope in complex with Fab, this linkage has angles equivalent to φ, ψ = −14◦,
6◦ and φ, ψ = 45◦, −6◦ (indicated by ‘X’s on the PMF plot). The 6RU simulations of GBSIII and Pn14
show sub-populations of anti-ψ conformations: transitions to this conformation are infrequent and
require long simulation times to become apparent. Indeed, anti-ψ conformations of this linkage were
not reported for the previous 50 ns simulation, which accounts for the smaller ψ standard deviation in
the average value reported by González-Outeiriño et al. (Table A1).
Appendix A.1.2. βDGlc(1→6)βDGlcNAc
This linkage is discussed in detail in the main text.
Appendix A.2. βDGal(1→4)βDGlcNAc
Comparison of the PMF maps reveals that addition of a N-Acetyl group restricts the range
of motion of the βDGal(1→4)βDGlcNAc linkage (Figure A1d, left) somewhat as compared to the
βDGal(1→4)βDGlc linkage (Figure A1b, left). The energy of the anti-ψ minimum is slightly lowered
and the anti-φ minimum raised. This is reflected in the narrower range of rotation in the simulations
of the GBSIII and Pn14 6RU oligosaccharides (Figure A1d). Rotation to the anti-ψ orientation of this
linkage is prevented by the proximity of the backbone βDGlc residue. In Pn14, the last RU which is
not in contact with a branch has a significant population of the anti-ψ conformer. This is in agreement
with simulations of both sLeX [20] and sLeX-5 [45], where the same linkage is constrained by the close
proximity of the branching αLFuc.
Appendix A.3. αDNeu5Ac(2→3)βDGal
The PMF for the charged αDNeu5Ac(2→3)βDGal disaccharide PMF (Figure A1c, left) was
computed in water and shows a very flexible linkage with multiple minima separated by low
energy barriers. The conformation of this sialyl linkage is known to have no fixed fixed standard
conformation and to be heavily dependent on the molecular environment [44]. Indeed, in contrast to
the flexibility of the disaccharide, in our simulation of GBSIII 6RU, a gauche conformation predominates
for this branching residue, with an average value of φ, ψ = −67◦, −4◦. The angle distribution for
this linkage is consistent with previous MD simulations of sLeX [20] and sLeX-5 [45]. In contrast,
González-Outeiriño et al. found that the (φ ≈ −180◦) anti-phi conformations predominated with the
mean of φ, ψ =−173◦,−11◦ and a population ratio for the anti/gauche states of approximately 96:4 [10].
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In the GBSIII DP2-Fab complex crystal structure [13], the unbound branch has angles equivalent to φ,
ψ = −80◦, −17◦ (close to our values) the bound branch has φ, ψ = 54◦, −4◦ (indicated by ‘X’s on the
PMF plot).
Appendix B. Branch Point in Tetrasaccharide
Figure A2. Rotation of the three-bond βDGlc(1→6)βDGlcNAc linkages in Pn14 and the effective
tetrasaccharide epitope previously identified (left) [14]. Time series scatter plots are superimposed on
the φ, ψ PMF (top row) and the φ, ω PMF (bottom row) for the two central βDGlc(1→6)βDGlcNAc
linkages for: (a) Pn14 φ, ψ; (b) Pn14 φ, ω; (c) tetrasaccharide φ, ψ; and (d) tetrasaccharide φ, ω.
References
1. Edmond, K.M.; Kortsalioudaki, C.; Scott, S.; Schrag, S.J.; Zaidi, A.K.M.; Cousens, S.; Heath, P.T. Group B
streptococcal disease in infants aged younger than 3 months: Systematic review and meta-analysis. Lancet
2012, 379, 547–556. [CrossRef]
2. Johnson, H.L.; Deloria-Knoll, M.; Levine, O.S.; Stoszek, S.K.; Hance, L.F.; Reithinger, R.; Muenz, L.;
O’Brien, K.L. Systematic evaluation of serotypes causing invasive pneumococcal disease among children
under five: The pneumococcal global serotype project. PLoS Med. 2010, 7, e1000348. [CrossRef] [PubMed]
3. Donders, G.; Halperin, S.; Devlieger, R.; Baker, S.; Forte, P.; Wittke, F.; Slobod, K.; Dull, P. Maternal
immunization with an investigational trivalent group B Streptococcal vaccine: A randomized controlled
trial. Obstet. Gynecol. 2016, 127, 213–221. [CrossRef] [PubMed]
4. Madhi, S.; Koen, A.; Cutland, C.; Jose, L.; Govender, N.; Wittke, F.; Olugbosi, M.; Sobanjo-ter Meulen, A.;
Baker, S.; Dull, P.; Narasimhan, V. Antibody Kinetics and Response to Routine Vaccinations in Infants
Born to Women Who Received an Investigational Trivalent Group B Streptococcus Polysaccharide
CRM197-Conjugate Vaccine During Pregnancy. Clin. Infect. Dis. 2017, 65, 1897–1904. [CrossRef] [PubMed]
5. Crumrine, M.; Fischer, G.; Balk, M. Immunochemical cross-reactions between type III group B streptococcus
and type 14 Streptococcus pneumoniae. Infect. Immun. 1979, 25, 960–963. [PubMed]
6. Guttormsen, H.K.; Baker, C.J.; Nahm, M.H.; Zughaier, L.C.P.S.M.; Edwards, M.S.; Kasper, D.L. Type III
Group B Streptococcal Polysaccharide Induces Antibodies That Cross-React with Streptococcus pneumoniae
Type 14. Infect. Immun. 2002, 70, 1724–1738. [CrossRef] [PubMed]
7. Safari, D.; Dekker, H.A.T.; Rijkers, G.T.; van der Ende, A.; Kamerling, J.P.; Snippe, H. The immune response
to group B streptococcus type III capsular polysaccharide is directed to the -Glc-GlcNAc-Gal- backbone
epitope. Glycoconj. J. 2011, 28, 557–562. [CrossRef] [PubMed]
Pharmaceuticals 2019, 12, 28 16 of 17
8. Kasper, D.L.; Baker, C.; Baltimore, R.; Crabb, J.; Schiffman, G.; Jennings, H. Immunodeterminant specificity
of human immunity to type III group B streptococcus. J. Exp. Med. 1979, 149, 327–339. [CrossRef] [PubMed]
9. Jennings, H.J.; Lugowski, C.; Kasper, D.L. Conformational aspects critical to the immunospecificity of the
type III group B streptococcal polysaccharide. Biochemistry 1981, 20, 4511–4518. [CrossRef] [PubMed]
10. González-Outeiriño, J.; Kadirvelraj, R.; Woods, R.J. Structural elucidation of type III group B Streptococcus
capsular polysaccharide using molecular dynamics simulations: The role of sialic acid. Carbohydr. Res. 2005,
340, 1007–1018. [CrossRef] [PubMed]
11. Kadirvelraj, R.; González-Outeiriño, J.; Foley, L.; Beckham, M.L.; Jennings, H.J.; Foote, S.; Ford, M.G.;
Woods, R.J. Understanding the bacterial polysaccharide antigenicity of Streptococcus agalactiae versus
Streptococcus pneumoniae. Proc. Natl. Acad. Sci. USA 2006, 103, 8149–8154. [CrossRef] [PubMed]
12. Jennings, H.J.; Katzenellenbogen, E.; Lugowski, C.; Michon, F.; Roy, R.; Kasper, L.D. Structure, conformation
and immunology of sialic acid containing polysaccharides of human pathogenic bacteria. Pure Appl. Chem.
1984, 56, 893–905. [CrossRef]
13. Carboni, F.; Adamo, R.; Fabbrini, M.; Ricco, R.D.; Cattaneo, V.; Brogioni, B.; Veggi, D.; Pinto, V.; Passalacqua, I.;
Oldrini, D.; Rappuoli, R.; Malito, E.; Margarita, I.R.; Berti, F. Structure of a protective epitope of group B
Streptococcus type III capsular polysaccharide. Proc. Natl. Acad. Sci. USA 2017, 114, 5017–5022. [CrossRef]
[PubMed]
14. Safari, D.; Dekker, H.A.T.; Joosten, J.A.; Michalik, D.; de Souza, A.C.; Adamo, R.; Lahmann, M.; Sundgren, A.;
Oscarson, S.; Kamerling, J.P.; Snippe, H. Identification of the smallest structure capable of evoking
opsonophagocytic antibodies against Streptococcus pneumoniae type 14. Infect. Immun. 2008, 76, 4615–4623.
[CrossRef] [PubMed]
15. Kurbatova, E.A.; Akhmatova, N.K.; Akhmatova, E.A.; Egorova, N.B.; Yastrebova, N.E.; Sukhova, E.V.;
Yashunsky, D.V.; Tsvetkov, Y.E.; Gening, M.L.; Nifantiev, N.E. Neoglycoconjugate of Tetrasaccharide
Representing One Repeating Unit of the Streptococcus pneumoniae Type 14 Capsular Polysaccharide Induces
the Production of Opsonizing IgG1 Antibodies and Possesses the Highest Protective Activity As Compared
to Hexa- and Octasaccharide Conjugates. Front. Immunol. 2017, 8, 659.
16. Varki, A.; Freeze, H.H.; Manzi, A.E. Overview of Glycoconjugate Analysis. Curr. Protoc. Protein Sci. 2009,
57, 12.
17. Kuttel, M.M.; Ravenscroft, N. The Role of Molecular Modeling in Predicting Carbohydrate Antigen
Conformation and Understanding Vaccine Immunogenicity. In Carbohydrate-Based Vaccines: From Concept
to Clinic; ACS Symposium Series; American Chemical Society: Washington, DC, USA, 2018; Volume 1290,
Chapter 7, pp. 139–173.
18. Kirschner, K.; Yongye, A.; Tschampel, S.; Gonzalez-Outeirino, J.; Daniels, C.; Foley, B.; Woods, R. GLYCAM06:
A Generalizable Biomolecular Force Field. Carbohydrates. J. Comput. Chem. 2008, 29, 622–655. [CrossRef]
19. Guvench, O.; Hatcher, E.; Venable, R.M.; Pastor, R.W.; Alexander, D.; MacKerell, J. CHARMM Additive
All-Atom Force Field for Glycosidic Linkages between Hexopyranoses. J. Chem. Theory Comput. 2009,
5, 2353–2370. [CrossRef]
20. Guvench, O.; Mallajosyula, S.S.; Raman, E.P.; Hatcher, E.; Vanommeslaeghe, K.; Foster, T.J.; Jamison, F.W., II;
MacKerell, A.D., Jr. CHARMM Additive All-Atom Force Field for Carbohydrate Derivatives and Its
Utility in Polysaccharide and CarbohydrateProtein Modeling. J. Chem. Theory Comput. 2011, 7, 3162–3180.
[CrossRef]
21. Mallajosyula, S.S.; Guvench, O.; Hatcher, E.; MacKerell, A.D., Jr. CHARMM Additive All-Atom Force Field
for Phosphate and Sulfate linked to carbohydrates. J. Chem. Theory Comput. 2012, 8, 759–776. [CrossRef]
22. Lewis, A.L.; Nizet, V.; Varki, A. Discovery and characterization of sialic acid O-acetylation in group B
Streptococcus. Proc. Natl. Acad. Sci. USA 2004, 101, 11123–11128. [CrossRef] [PubMed]
23. Pannaraj, P.S.; Edwards, M.S.; Ewing, K.T.; Lewis, A.L.; Rencha, M.A.; Baker, C.J. Group B streptococcal conjugate
vaccines elicit functional antibodies independent of strain O-acetylation. Vaccine 2009, 27, 4452–4456. [CrossRef]
[PubMed]
24. Kuttel, M.M.; Jackson, G.E.; Mafata, M.; Ravenscroft, N. Capsular polysaccharide conformations in
pneumococcal serotypes 19F and 19A. Carbohydr. Res. 2015, 406, 27–33. [CrossRef] [PubMed]
25. Kuttel, M.M.; Timol, Z.; Ravenscroft, N. Cross-protection in Neisseria meningitidis serogroups Y and W
polysaccharides: A comparative conformational analysis. Carbohydr. Res. 2017, 446–447, 40–47. [CrossRef]
[PubMed]
Pharmaceuticals 2019, 12, 28 17 of 17
26. Hlozek, J.; Kuttel, M.M.; Ravenscroft, N. Conformations of Neisseria meningitidis serogroup A and X
polysaccharides: The effects of chain length and O-acetylation. Carbohyd. Res. 2018, 465, 44–51. [CrossRef]
[PubMed]
27. Laio, A.; Parrinello, M. Escaping free energy minima. Proc. Natl. Acad. Sci. USA 2002, 99, 12562–12565.
[CrossRef] [PubMed]
28. Phillips, J.C.; Braun, R.; Wang, W.; Gumbart, J.; Tajkhorshid, E.; Villa, E.; Chipot, C.; Skeel, R.D.; Kale, L.;
Schulten, K. Scalable Molecular Dynamics with NAMD. J. Comput. Chem. 2005, 26, 1781–1802. [CrossRef]
29. Yang, M.; MacKerell, A.D. Conformational Sampling of Oligosaccharides Using Hamiltonian Replica
Exchange with Two-Dimensional Dihedral Biasing Potentials and the Weighted Histogram Analysis Method
(WHAM). J. Chem. Theory Comput. 2015, 11, 788–799. [CrossRef]
30. Kuttel, M.M. Conformational free energy maps for globobiose (α-D-Gal-(1-4)-β-D-Gal) in implicit and explict
aqueous solution. Carbohydr. Res. 2008, 343, 1091–1098. [CrossRef]
31. Stone, J.E.; Phillips, J.C.; Freddolino, P.L.; Hardy, J.; Trabuco, L.G.; Schulten, K. Accelerating Molecular
Modeling Applications with Graphics Processors. J. Comput. Chem. 2007, 28, 2618–2639. [CrossRef]
32. Guvench, O.; Greene, S.N.; Kamath, G.; Brady, J.W.; Venable, R.M.; Pastor, R.W.; MacKerell, A.D. Additive
Empirical Force Field for Hexopyranose Monosaccharides. J. Comput. Chem. 2008, 29, 2543–2564. [CrossRef]
[PubMed]
33. Jorgensen, W.L.; Chandrasekhar, J.; Madura, J.D.; Impey, R.W.; Klein, M.L. Comparison of simple potential
functions for simulations of liquid water. J. Chem. Phys. 1983, 79, 926–935. [CrossRef]
34. Kuttel, M.; Ravenscroft, N.; Foschiatti, M.; Cescutti, P.; Rizzo, R. Conformational properties of two
exopolysaccharides produced by Inquilinus limosus, a cystic fibrosis lung pathogen. Carbohydr. Res. 2012,
350, 40–48. [CrossRef] [PubMed]
35. Kuttel, M.M.; Stähle, J.; Widmalm, G. CarbBuilder: Software for Building Molecular Models of Complex
Oligo- and Polysaccharide Structures. J. Comput. Chem. 2016, 37, 2098–2105. [CrossRef] [PubMed]
36. Humphrey, W.; Dalke, A.; Schulten, K. VMD—Visual Molecular Dynamics. J. Mol. Graph. 1996, 14, 33–38.
[CrossRef]
37. Feller, S.E.; Zhang, Y.; Pastor, R.W.; Brooks, B.R. Constant pressure molecular dynamics simulation: The
Langevin piston method. J. Chem. Phys. 1995, 103, 4613–4621. [CrossRef]
38. Nose, S.; Lein, M.L. Constant pressure molecular dynamics for molecular systems. Mol. Phys. 1983, 50,
1055–1076. [CrossRef]
39. Hoover, W.G. Canonical dynamics: Equilibrium phase-space distributions. Phys. Rev. A 1985, 31. [CrossRef]
40. Cross, S.; Kuttel, M.M.; Stone, J.E.; Gain, J.E. Visualisation of Cyclic and Multi-Branched Molecules with
VMD. J. Mol. Graph. Model. 2009, 28, 131–139. [CrossRef] [PubMed]
41. Heyer, L.J.; Kruglyak, S.; Yooseph, S. Exploring Expression Data: Identification and Analysis of Coexpressed
Genes. Genome Res. 1999, 9, 1106–1115. [CrossRef] [PubMed]
42. Lundborg, M.; Widmalm, G. Structure Analysis of Glycans by NMR Chemical Shift Prediction. Anal. Chem.
2011, 83, 1514–1517. [CrossRef] [PubMed]
43. Nishida, Y.; Hori, H.; Ohrui, H.; Meguro, H. 1H-NMR analyses of rotameric distributions of C5-C6 bonds of
D-glucopyranoses in solution. J. Carbohydr. Chem. 1988, 7, 239–250. [CrossRef]
44. Miyazaki, T.; Sato, H.; Sakakibara, T.; Kajihara, Y. An Approach to the Precise Chemoenzymatic
Synthesis of 13C-Labeled Sialyloligosaccharide on an Intact Glycoprotein: A Novel One-Pot [3-13C]-Labeling
Method for Sialic Acid Analogues by Control of the Reversible Aldolase Reaction, Enzymatic
Synthesis of [3-13C]-NeuAc-α-(2→3)-[U-13C]-Gal-β-(1→4)-GlcNAc-β- Sequence onto Glycoprotein, and Its
Conformational Analysis by Developed NMR Techniques. J. Am. Chem. Soc. 2000, 122, 5678–5694.
45. Battistel, M.D.; Azurmendi, H.F.; Frank, M.; Freedberg, D.I. Uncovering Nonconventional and Conventional
Hydrogen Bonds in Oligosaccharides through NMR Experiments and Molecular Modeling: Application to
Sialyl Lewis X. J. Am. Chem. Soc. 2015, 137, 13444–13447. [CrossRef] [PubMed]
c© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
